NASDAQ · Biotechnology

TARA (TARA) Stock

$3.92 -2.73% NASDAQ: TARA Healthcare

Valuation

MetricValue
Price$3.92
Market Cap$220.32M
P/E Ratio-3.55
P/B Ratio0.94
P/S Ratio0.00
EPS (TTM)$-1.34
52-Week High$7.82
52-Week Low$2.77
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-29.08%
ROA-27.27%
ROCE-33.16%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.02
Current Ratio14.55

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-47.0M$-67.0M$-44.0M$-49.0M$-65.0M
Net Profit$-47.0M$-66.0M$-40.0M$-45.0M$-57.0M
EPS$-4.20$-5.86$-3.57$-2.17$-1.34
Op Margin

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$173.0M$113.0M$79.0M$181.0M$209.0M
Total Liabilities$11.0M$11.0M$11.0M$14.0M$13.0M
Cash$36.0M$24.0M$40.0M$163.0M$50.0M
Borrowings$7.0M$6.0M$5.0M$4.0M$3.0M

Latest News

What Makes Protara Therapeutics (TARA) a New Buy Stock Zacks · Jul 21, 2026 Protara Therapeutics CMO Leonardo Viana Nicacio Resigns MT Newswires · Jun 30, 2026 Non-muscle Invasive Bladder Cancer Market Dynamics to Shift During the Forecast Period (2026-2036) as Novel Targeted and Gene Therapies Enter Late-Stage Development | DelveInsight PR Newswire · Jun 23, 2026 Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million Motley Fool · May 31, 2026 Oppenheimer Adjusts Protara Therapeutics PT to $28 From $25, Maintains Outperform Rating MT Newswires · May 20, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-35.0M$-26.0M$-38.0M$-36.0M$-56.0M
Investing Cash Flow$-99.0M$15.0M$53.0M$19.0M$-140.0M
Financing Cash Flow$0$0$0$4.0M$0
Net Cash Flow$-133.0M$-12.0M$15.0M$123.0M$-113.0M
Free Cash Flow$-35.0M$-27.0M$-38.0M$-36.0M$-56.0M

Valuation & Return Ratios

MetricValue
PEG Ratio
EV / EBITDA
FCF Yield-32.97%
Quick Ratio15.69
Interest Coverage
Return 1Y19.17%
Return 3Y37.88%
Return 5Y-51.77%

Ownership

Insiders Held2.42%
Institutions Held81.11%
Institutions Float Held83.13%
Institutional HolderSharesReport Date
Janus Henderson Group PLC5,207,0112026-03-31
Blackrock Inc.3,394,9682026-03-31
Velan Capital Investment Management LP2,834,6522026-03-31
Millennium Management Llc2,831,2082026-03-31
Blackstone Inc2,265,5142026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CDXS $1.47 -2.00% -5.06 $133.62M 0.00%
GNFTGenfit S.A. $8.95 +4.07% 261.07 $445.68M 0.00%
IVVD $0.55 +3.10% -3.53 $162.51M 0.00%
MDWD $14.35 -1.85% -7.94 $184.34M 0.00%
NTHINeonc Technologies Holdings, Inc. $3.44 +0.29% -1.77 $89.21M 0.00%

About TARA

TARA is led by CEO Jesse Shefferman, employs 28 people, headquartered in US, publicly traded since 2014.

TARA stock trades at $3.92 with a market capitalization of $220.32M. The stock is valued at a price-to-earnings (P/E) ratio of -3.55, price-to-book of 0.94, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $2.77 and $7.82, and currently trades 49.9% below its 52-week high.

On profitability, TARA generates a return on equity (ROE) of -29.08%, return on capital employed of -33.16%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides